Skip to main content

Advertisement

SpringerLink
Log in

Vasohibin-1 expression detected by immunohistochemistry correlates with prognosis in non-small cell lung cancer

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Vasohibin-1 (VASH1) is a newly discovered angiogenesis inhibitor that is specifically expressed in human vascular endothelial cells in response to vascular endothelial growth factor and fibroblast growth factor-2. This study aimed to evaluate the expression of VASH1 in non-small cell lung cancer (NSCLC) and correlates its expression with the clinicopathological parameters and prognosis of the disease. Immunohistochemical analysis was used to determine the expression of VASH1 in NSCLC tissue and adjacent normal tissue from 84 patients. The relationship between VASH1 expression and clinicopathological indicators was examined with the chi-squared test. Moreover, the survival rate was calculated with the Kaplan–Meier survivor curve. Finally, the correlation between the indicators and patient survival was estimated with Cox analysis. VASH1 was high expressed in 63.1 % of NSCLC tissues versus 21.4 % of adjacent tissues (P < 0.01). High VASH1 expression in NSCLC tissue was correlated with clinicopathological features including lymph node status (P = 0.024) and TNM stage (P = 0.036). The Kaplan–Meier curve indicated that the patients with high VASH1 expression had significantly shorter survival than those with low VASH1 expression. In the multivariate Cox regression model, high VASH1 expression was identified as an independent prognostic factor for patients with NSCLC. High VASH1 expression is predictive of poor prognosis of NSCLC, implying that VASH1 may be a promising new target for targeted therapies for NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.

    Article  PubMed  Google Scholar 

  2. Jema A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.

    Article  Google Scholar 

  3. Powell CA, Halmos B, Nana-Sinkam SP. Update in lung cancer and mesothelioma 2012. Am J Respir Crit Care Med. 2013;188(2):157–66.

    Article  CAS  PubMed  Google Scholar 

  4. Pirker R. Novel drugs against non-small-cell lung cancer. Curr Opin Oncol. 2014;26(2):145–51.

    Article  CAS  PubMed  Google Scholar 

  5. Cao Z, Bao M, Miele L, et al. Tumour vasculogenic mimicry is associated with poor prognosis of human cancer patients: a systemic review and meta-analysis. Eur J Cancer. 2013;49(18):3914–23.

    Article  PubMed  Google Scholar 

  6. Yazdani S, Miki Y, Tamaki K, et al. Proliferation and maturation of intratumoral blood vessels in non-small cell lung cancer. Hum Pathol. 2013;44(8):1586–96.

    Article  PubMed  Google Scholar 

  7. Aggarwal C, Somaiah N, Simon G. Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed? Cancer Biol Ther. 2012;13(5):247–63.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Salgia R. Prognostic significance of angiogenesis and angiogenic growth factors in non-small cell lung cancer. Cancer. 2011;117(17):3889–99.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423–37.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Fagiani E, Christofori G. Angiopoietins in angiogenesis. Cancer Lett. 2013;49(1):121–31.

    Google Scholar 

  11. Sato Y. The vasohibin family: novel regulators of angiogenesis. Vascul Pharmacol. 2012;56(5–6):262–6.

    Article  CAS  PubMed  Google Scholar 

  12. Sato Y. The vasohibin family: a novel family for angiogenesis regulation. J Biochem. 2013;153(1):5–11.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Wehland M, Bauer J, Magnusson NE, et al. Biomarkers for anti-angiogenic therapy in cancer. Int J Mol Sci. 2013;14(5):9338–64.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Cao R, Ji H, Feng N, et al. Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis. Proc Natl Acad Sci USA. 2012;109(39):15894–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Kubota Y. Tumor angiogenesis and anti-angiogenic therapy. Keio J Med. 2012;61(2):47–56.

    Article  CAS  PubMed  Google Scholar 

  16. Eklund L, Saharinen P. Angiopoietin signaling in the vasculature. Exp Cell Res. 2013;319(9):1271–80.

    Article  CAS  PubMed  Google Scholar 

  17. Claesson-Welsh L, Welsh M. VEGFA and tumour angiogenesis. J Intern Med. 2013;273(2):114–27.

    Article  CAS  PubMed  Google Scholar 

  18. Tamaki K, Sasano H, Maruo Y, et al. Vasohibin-1 as a potential predictor of aggressive behavior of ductal carcinoma in situ of the breast. Cancer Sci. 2010;101(4):1051–8.

    Article  CAS  PubMed  Google Scholar 

  19. Wang Q, Tian X, Zhang C, et al. Upregulation of vasohibin-1 expression with angiogenesis and poor prognosis of hepatocellular carcinoma after curative surgery. Med Oncol. 2012;29(4):2727–36.

    Article  CAS  PubMed  Google Scholar 

  20. Kanomata N, Sato Y, Miyaji Y, et al. Vasohibin-1 is a new predictor of disease-free survival in operated patients with renal cell carcinoma. J Clin Pathol. 2013;66(7):613–9.

    Article  CAS  PubMed  Google Scholar 

  21. Takahashi Y, Koyanagi T, Suzuki Y, et al. Vasohibin-2 expressed in human serous ovarian adenocarcinoma accelerates tumor growth by promoting angiogenesis. Mol Cancer Res. 2012;10(9):1135–46.

    Article  CAS  PubMed  Google Scholar 

  22. Yan Y, Shen Z, Ye Y, et al. A novel molecular marker of prognosis in colorectal cancer: vasohibin-1. Med Oncol. 2014;31(2):816.

    Article  PubMed  Google Scholar 

  23. Zhao G, Yang Y, Tang Y, et al. Reduced expression of vasohibin-1 is associated with clinicopathological features in renal cell carcinoma. Med Oncol. 2012;29(5):3325–34.

    Article  CAS  PubMed  Google Scholar 

  24. Yoshinaga K, Ito K, Moriya T, et al. Roles of intrinsic angiogenesis inhibitor, vasohibin, in cervical carcinomas. Cancer Sci. 2011;102(2):446–51.

    Article  CAS  PubMed  Google Scholar 

  25. Shen Z, Kauttu T, Seppänen H, et al. Vasohibin-1 and vasohibin-2 expression in gastric cancer cells and TAMs. Med Oncol. 2012;29(4):2718–26.

    Article  CAS  PubMed  Google Scholar 

  26. Miyazaki Y, Kosaka T, Mikami S, et al. The prognostic significance of vasohibin-1 expression in patients with upper urinary tract urothelial carcinoma. Clin Cancer Res. 2012;18(15):4145–53.

    Article  CAS  PubMed  Google Scholar 

  27. Shirasuna K, Kobayashi A, Nitta A, et al. Possible action of vasohibin-1 as an inhibitor in the regulation of vascularization of the bovine corpus luteum. Reproduction. 2012;143(4):491–500.

    Article  CAS  PubMed  Google Scholar 

  28. Ito S, Miyashita H, Suzuki Y, et al. Enhanced cancer metastasis in mice deficient in vasohibin-1 gene. PLoS One. 2013;8(9):e73931.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Xue X, Gao W, Sun B, et al. Vasohibin 2 is transcriptionally activated and promotes angiogenesis in hepatocellular carcinoma. Oncogene. 2013;32(13):1724–34.

    Article  CAS  PubMed  Google Scholar 

  30. Takahashi Y, Koyanagi T, Suzuki Y, et al. Vasohibin-2 expressed in human serous ovarian adenocarcinoma accelerates tumor growth by promoting angiogenesis. Mol Cancer Res. 2012;10(9):1135–46.

    Article  CAS  PubMed  Google Scholar 

  31. Heishi T, Hosaka T, Suzuki Y, et al. Endogenous angiogenesis inhibitor vasohibin1 exhibits broad-spectrum antilymphangiogenic activity and suppresses lymph node metastasis. Am J Pathol. 2010;176(4):1950–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  32. Li D, Zhou K, Wang S, et al. Recombinant adenovirus encoding vasohibin prevents tumor angiogenesis and inhibits tumor growth. Cancer Sci. 2010;101(2):448–52.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors report no conflicts of interest in this work.

Author information

Authors and Affiliations

  1. Department of Oncology, The First Hospital of Lanzhou University (The Branch Hospital of Donggang), Lanzhou, 730000, Gansu Province, China

    Tao Zhang, Xiao-Ming Hou, Xiao-Jun Liu & Da Zhao

  2. Department of Thoracic Oncology, Tumor Hospital Affiliated to Xinjiang Medical University, Ürümqi, 830011, Xinjiang Province, China

    Ting-Ting Yu & Li Shan

  3. Department of Respiratory, The Second People’s Hospital of Pingliang, Pingliang, 744000, Gansu Province, China

    Dong-Ming Zhang

Authors
  1. Tao Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ting-Ting Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dong-Ming Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiao-Ming Hou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiao-Jun Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Da Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Li Shan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Da Zhao or Li Shan.

Additional information

Tao Zhang and Ting-Ting Yu have contributed equally to this paper.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, T., Yu, TT., Zhang, DM. et al. Vasohibin-1 expression detected by immunohistochemistry correlates with prognosis in non-small cell lung cancer. Med Oncol 31, 963 (2014). https://doi.org/10.1007/s12032-014-0963-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-014-0963-y

Keywords

Search

Navigation